China-based Kexing Biopharm (SHA: 688136) and Bio-Thera Solutions Ltd (SHA: 688177) have formed a strategic alliance to explore international pharmaceutical markets. The partnership aims to leverage the companies’ respective strengths in research and development, manufacturing, and commercialization. Financial details were not disclosed.
Bio-Thera’s Portfolio
Bio-Thera has four marketed biologic drugs:
- Qletli (adalimumab biosimilar)
- Avzivi (bevacizumab biosimilar)
- Shiruili (tocilizumab biosimilar)
- Beitaning (batifiban)
Two products, Tofidence and Avzivi, are approved in the US and European Union. Another product, BAT2206 (ustekinumab biosimilar), is awaiting regulatory decisions in China, the US, and EU.
Strategic Outlook
The alliance will enable both companies to expand their global footprint by combining R&D, manufacturing, and commercial capabilities. Bio-Thera’s existing international approvals and pipeline will be key assets in the partnership.-Fineline Info & Tech
